Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
MAZE Stock Chart & Stats
$49.00
--
Market closed
$49.00
--
Day’s Range― - ―
52-Week Range$6.71 - $53.65
Previous CloseN/A
VolumeN/A
Average Volume (3M)527.25K
Market Cap
$1.53B
Enterprise Value$1.36B
Total Cash (Recent Filing)$341.92M
Total Debt (Recent Filing)$23.31M
Price to Earnings (P/E)―
Beta0.94
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,119,446
10 Day Avg. Volume833,633
30 Day Avg. Volume527,246
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-15.79
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.10K
Enterprise Value/Ebitda-10.05
Forecast
1Y Price Target
$66.50Price Target Upside35.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyAnalyst notes that Phase 2 HORIZON results showed MZE829 produced meaningful reductions in urine protein in focal segmental glomerulosclerosis and across APOL1-mediated kidney disease even on top of optimized background therapies, supporting strong clinical activity.
Pipeline Valuation And PlatformAnalyst highlights MZE782's strong early markers of effect and the company's genetically driven precision-medicine platform, providing a valuation cushion and reducing reliance on a single asset.
Safety ProfileReported safety profile for MZE829 showed no treatment-related serious adverse events and only mild to moderate side effects, lowering clinical development risk.
Bears Say
Limited Sample SizeSmall number of evaluable patients in the efficacy analysis limits confidence in the findings and requires larger, controlled studies to confirm treatment effects.
Research Conflicts Of InterestResearch coverage may be subject to conflicts of interest because the firm does business with covered companies, which could affect report objectivity and investor interpretation of the data.
Uncertainty In Diabetic PopulationUncertainty about effectiveness in patients with diabetes means additional evidence is necessary to determine the therapy's role and could constrain market expansion.
Maze Therapeutics, Inc. News
MAZE FAQ
What was Maze Therapeutics, Inc.’s price range in the past 12 months?
Maze Therapeutics, Inc. lowest stock price was $6.71 and its highest was $53.65 in the past 12 months.
What is Maze Therapeutics, Inc.’s market cap?
Maze Therapeutics, Inc.’s market cap is $1.53B.
When is Maze Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Maze Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Maze Therapeutics, Inc. overvalued?
According to Wall Street analysts Maze Therapeutics, Inc.’s price is currently Undervalued.
Does Maze Therapeutics, Inc. pay dividends?
Maze Therapeutics, Inc. does not currently pay dividends.
What is Maze Therapeutics, Inc.’s EPS estimate?
Maze Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Maze Therapeutics, Inc. have?
Maze Therapeutics, Inc. has 48,119,446 shares outstanding.
What happened to Maze Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Maze Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MAZE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Maze Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.50 (35.71% Upside)
$66.50 (35.71% Upside)
Blogger Sentiment
Bullish
MAZE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 20.6%
Last 30 Days ▲ 24.9%
Last 30 Days ▲ 24.9%
News Sentiment
Bullish
Bullish news 76%
Bearish news 24%
Bearish news 24%
Technicals
SMA
Positive
20 days / 200 days
Momentum
339.85%
12-Months-Change
Fundamentals
Return on Equity
-44.62%
Trailing 12-Months
Asset Growth
119.27%
Trailing 12-Months
Company Description
Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
MAZE Stock 12 Month Forecast
Average Price Target
$66.50
▲(35.71% Upside)
Technical Analysis
Ownership Overview
12.09% Insiders
6.22% Mutual Funds
70.58% Other Institutional Investors
4.81% Public Companies and
Individual Investors